PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26505347-0	2015	AMP-activated protein kinase regulates autophagic protection against cisplatin-induced tissue injury in the kidney.	Cisplatin	69-78	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-28	
26505347-7	2015	Interestingly, in the kidney, cisplatin treatment can activate AMP-activated protein kinase (AMPK), a signaling molecule that is also critical for p53-mediated inactivation of mammalian target of rapamycin (mTOR) pathways.	Cisplatin	30-39	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	63-91	
26505347-7	2015	Interestingly, in the kidney, cisplatin treatment can activate AMP-activated protein kinase (AMPK), a signaling molecule that is also critical for p53-mediated inactivation of mammalian target of rapamycin (mTOR) pathways.	Cisplatin	30-39	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	93-97	
26505347-8	2015	As a result, inhibition or knockdown of AMPK can lead to repressed autophagy in cisplatin-induced AKI, resulting in more DNA damage.	Cisplatin	80-89	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	40-44	
26505347-9	2015	Activation of AMPK regulates autophagy during cisplatin-induced AKI.	Cisplatin	46-55	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	14-18	
26505347-10	2015	Given the fact that p53 can regulate autophagy by inactivating mTOR via AMPK, our results suggest that the p53 pathway may also play a critical role in the pathogenesis of cisplatin-induced renal damage.	Cisplatin	172-181	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	72-76